Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1986 1
1988 1
1989 1
1990 1
1992 1
1994 1
1995 1
1996 1
1997 2
1998 3
1999 1
2000 4
2001 1
2004 2
2007 4
2008 6
2009 4
2010 10
2011 11
2012 13
2013 12
2014 25
2015 24
2016 24
2017 30
2018 30
2019 52
2020 67
2021 125
2022 155
2023 240
2024 114

Text availability

Article attribute

Article type

Publication date

Search Results

866 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Kaewnimit
Page 1
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Brannan SK, et al. N Engl J Med. 2021 Feb 25;384(8):717-726. doi: 10.1056/NEJMoa2017015. N Engl J Med. 2021. PMID: 33626254 Free PMC article. Clinical Trial.
Larger and longer trials are required to determine the efficacy and safety of xanomeline-trospium in patients with schizophrenia. (Funded by Karuna Therapeutics and the Wellcome Trust; ClinicalTrials.gov number, NCT03697252.)....
Larger and longer trials are required to determine the efficacy and safety of xanomeline-trospium in patients with schizophrenia. (Funded by …
The Opioid Crisis and the Future of Addiction and Pain Therapeutics.
Coussens NP, Sittampalam GS, Jonson SG, Hall MD, Gorby HE, Tamiz AP, McManus OB, Felder CC, Rasmussen K. Coussens NP, et al. J Pharmacol Exp Ther. 2019 Nov;371(2):396-408. doi: 10.1124/jpet.119.259408. Epub 2019 Sep 3. J Pharmacol Exp Ther. 2019. PMID: 31481516 Free PMC article. Review.
Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning.
Nonnenmacher M, Wang W, Child MA, Ren XQ, Huang C, Ren AZ, Tocci J, Chen Q, Bittner K, Tyson K, Pande N, Chung CH, Paul SM, Hou J. Nonnenmacher M, et al. Mol Ther Methods Clin Dev. 2020 Dec 23;20:366-378. doi: 10.1016/j.omtm.2020.12.006. eCollection 2021 Mar 12. Mol Ther Methods Clin Dev. 2020. PMID: 33553485 Free PMC article.
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Kaul I, et al. Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104575 Clinical Trial.
Results from additional trials, including the identical EMERGENT-3 trial and the 52-week, open-label EMERGENT-4 and EMERGENT-5 trials, will provide additional information on the efficacy and safety of KarXT in people with schizophrenia. FUNDING: Karuna Therapeutics....
Results from additional trials, including the identical EMERGENT-3 trial and the 52-week, open-label EMERGENT-4 and EMERGENT-5 trials, will …
Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis.
Liss JL, Seleri Assunção S, Cummings J, Atri A, Geldmacher DS, Candela SF, Devanand DP, Fillit HM, Susman J, Mintzer J, Bittner T, Brunton SA, Kerwin DR, Jackson WC, Small GW, Grossberg GT, Clevenger CK, Cotter V, Stefanacci R, Wise-Brown A, Sabbagh MN. Liss JL, et al. J Intern Med. 2021 Aug;290(2):310-334. doi: 10.1111/joim.13244. Epub 2021 Mar 31. J Intern Med. 2021. PMID: 33458891 Free PMC article. Review.
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J. Krystal JH, et al. Lancet. 2022 Dec 17;400(10369):2210-2220. doi: 10.1016/S0140-6736(22)01990-0. Lancet. 2022. PMID: 36528376 Clinical Trial.
866 results